#Sensei biotherapeutics trial#

Change value during other periods is calculated as the difference between the last trade and the most recent settle. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Sources: FactSet, Tullett PrebonĬommodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Sources: FactSet, Tullett PrebonĬurrencies: Currency quotes are updated in real-time.

Sources: FactSet, Dow Jonesīonds: Bond quotes are updated in real-time. Sources: FactSet, Dow JonesĮTF Movers: Includes ETFs & ETNs with volume of at least 50,000. Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Overview page represent trading in all U.S. Indexes: Index quotes may be real-time or delayed as per exchange requirements refer to time stamps for information on any delays. Copyright 2019© FactSet Research Systems Inc. Fundamental company data and analyst estimates provided by FactSet. International stock quotes are delayed as per exchange requirements. stock quotes reflect trades reported through Nasdaq only comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. Earlier stage programs include SNS-401, a ImmunoPhage™ cocktail for the treatment of Merkel Cell Carcinoma, and SNS-VISTA, an antibody-based therapeutic targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA).Stocks: Real-time U.S.

#Sensei biotherapeutics trial#

The company’s most advanced immunotherapy, SNS-301, a first-in-class ImmunoPhage™ targeting the tumor antigen Aspartyl beta Hydroxylase (ASPH), is currently in a Phase 1/2 clinical trial in patients with advanced Squamous Cell Carcinoma of the Head and Neck. The platform enables efficient, scalable and cost-effective manufacturing to support all of Sensei’s clinical programs. Using the ImmunoPhage™ platform, Sensei is developing a library of ImmunoPhage, called Phortress™, to target multiple tumor-associated antigens to create a personalized yet off-the-shelf cocktail approach for treating cancer patients. The company has developed a proprietary bacteriophage-based platform, ImmunoPhage™, that enables the rapid generation of immune activating therapeutic agents that fully engage the immune system. Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. Industry: Research and Development in Biotechnology

It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. Indicates a company's profitability in relation to its total assets. The rate at which the company's net income has increased to the same quarter one year ago. It indicates the company's profitability. Net income divided by revenue of the last 4 quarters.

Net Income is the profit after all expenses have been deducted from the total revenue. It indicates the efficiency of using their resources to produce goods or services.Įarnings before tax and interest payments. Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. Revenue is the sum of all cash flow into the company. However, the ratio is difficult to compare between industries where common amounts of debt vary. Price to Book Ratio is the Market cap divided by the Book value of the companyĪ higher ratio indicates a higher risk. Market cap divided by the revenue in the most recent year. A lower PEG could mean that a stock is undervalued.Įarnings divided by outstanding shares. The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. Ratio between share price and earnings per share.